What changed 10-Q

Item 5. Other Information

2024-11-05 compared with 2024-08-16 · 7 added, 9 removed, 14 unchanged (53% of the section changed)

OTHER INFORMATION

During the quarter ended June 30, 2024,

no director or officer of the Company adopted

or terminated

a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in

Item 408(a) of Regulation S-K.

During the quarter

ended September 30, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule

10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

7 unchanged sentences

Filed herewith.

** Furnished herewith.

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on August 16, 2024.

Pursuant to the

requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned

thereunto duly authorized, on November 5, 2024.

SUNSHINE BIOPHARMA INC.

2 unchanged sentences

Camille Sebaaly

Chief Financial Officer (principal financial and accounting officer)

Chief Financial Officer (principal financial and accounting

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.